|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other driver biomarkers in lung cancer (point mutations and rearrangements in specific genes including Her2, BRAF, NUT, MET, ROS1, DDR2, FGFR1, KRAS, and PTEN) might potentially provide additional information for clinical decision making.
|
24420742 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we tested for possible aberrations of the c-erbB-2 gene in the region of the transmembrane domain in surgical specimens of human primary lung cancer from 190 patients, and also examined 24 metastases and 26 specimens of noncancerous portions of the lung of the same patients.
|
1483946 |
1992 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that heterodimers of MET with EGFR, HER2, HER3, or RET have differential roles in tumour development, and they provide new insight into the function of trans-phosphorylated RTKs as heterodimerisation partners of MET in lung cancer with MET amplification.
|
21847121 |
2011 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib.
|
26559459 |
2015 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method.
|
28152008 |
2017 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade.
|
30449325 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
|
17626639 |
2007 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
|
18089823 |
2007 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Given the high prevalence of lung cancer worldwide and the availability of standard and investigational therapies targeting HER2, routine clinical genotyping of lung ADC should include HER2.
|
22761469 |
2012 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Eleven human lung cancer cell lines, including four derived from small cell lung cancer (SCLC) and seven derived from NSCLC were also examined for altered c-erbB-2 gene expression.
|
2569928 |
1989 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.
|
22372864 |
2012 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After MRI diagnosis, breast and lung cancer brain metastases were successfully treated with similar tumor-targeted nanoconjugates carrying molecular inhibitors of EGFR or HER2 instead of imaging contrast agent.
|
25906400 |
2015 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this report we evaluated Her-2/neu gene expression by fluorescence in situ hybridization (FISH) and the cell surface expression of the Her-2/neu receptor by immunohistochemistry using the HercepTest and by FACS analysis in 31 lung cancer cell lines with 5 breast cancer cell lines as controls.
|
11595720 |
2001 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer of never smokers exhibited significantly higher ctDNA mutation rates as well as higher EGFR and ERBB2 mutations than ever smokers.
|
28472989 |
2017 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer.
|
29941010 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess antigen reactivity, <sup>89</sup>Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer.
|
30442753 |
2019 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with lung cancer and HER2 mutations developed more brain metastases on treatment than patients with KRAS mutations (28% vs 8%; hazard ratio [HR], 5.2; P < .001) and trended more than patients with EGFR mutations (28% vs 16%; HR, 1.7; P = .06).
|
31469421 |
2019 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 and lung cancer.
|
24134423 |
2013 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study involves ligand-based pharmacophore modeling of various kinases, including EGFR (T790 M), cMET, ErbB2, FGFR and ALK, which are well established targets of normal as well resistant lung cancer.
|
30343450 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraffin-embedded sections from 42 cases with lung carcinoma were stained immunohistochemically using the Avidin-Biotin Horseradish Peroxidase method to search for c-erbB-2 reaction.
|
11847606 |
2002 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we show that the major lung cancer-derived ERBB2 mutants, including the most frequent mutation, A775insYVMA, lead to oncogenic transformation in a cellular assay.
|
17311002 |
2007 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed mutations in EGFR, KRAS, TP53, and ERBB2 in 198 surgically resected lung cancer specimens.
|
18334834 |
2008 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.
|
15753357 |
2005 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
|
20459769 |
2010 |